We are on a mission to completely change the face of liver disease treatment with our breakthrough stem cell-based therapy as an alternative to transplant.
With HepaTx technology, liver regeneration through hepatocyte infusion is both clinically and economically advantageous for patients, physicians and investors alike.
Efficiency
Our go-to-market strategy is faster and more efficient than traditional development pathways. We achieve this through a combination of our scalable, fully-defined manufacturing process and our innovative regulatory strategy that will allow us to reach critical milestones efficiently.
Exclusivity
Our exclusive world-wide license from Stanford covers critical technology. We are on a path to a comprehensive IP portfolio that will include additional manufacturing technologies as well as therapeutic applications.
Accessibilty
Unlike hepatocytes from cadavers or liver donors, our supply is unlimited. Our allogeneic cell therapy product can be distributed for on-demand availability.
Expertise
We have an experienced, talented team supported by expert industry and academic advisors to execute our plan.
HepaTx Pipeline
The HepaTx pipeline spans initial niche indications with lower developmental costs, rapid regulatory approval paths and large market chronic liver disease indications.
A1ATD: Alpha 1 anti-trypsin deficiency
PKU: Phenylketonuria
NASH: Non-alcoholic steatohepatitis
